Hematological Malignancies

CMT / Chemo for early stage

• No RCT • RT outcome is excellent. Difficult to improve on . • Limited data on role of CMT in early stage dis – Canadian data on short course ABVD suggests benefit – but other studies ( MDACC, GHSG, Harvard ) show no benefit – RT alone remains standard • Chemo alone strategy in children : limited data • Rituximab alone : limited data (GHSG 28 pts, Stanford 13 pts): – 100% response, but 25% relapse. Not recommended.